RECRUITING

Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To learn if hypophysectomy (treatment of the pituitary gland) using a type of radiation treatment called stereotactic radiosurgery (SRS) can help to relieve cancer-related pain.

Official Title

Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain

Quick Facts

Study Start:2025-01-06

Study Completion:2027-07-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06287515

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age ≥ 18 years old on the day of signing informed consent and willing and able to sign a written informed consent. * English fluency in order to complete PROs and neurocognitive assessment * Pathologic or cytologic confirmation of malignancy. * Poorly controlled intractable nociceptive or mixed pain limiting function or quality of life. Participants must have exhausted or not a candidate for standard of care pain control measures such as opioids, injections/ablations, conventional radiation therapy, or surgical intervention with a curative intent and pain limiting function that affects the participants quality of life in the judgment of the treating physician. Refractory status will require at least consultation and two follow-up visits with pain specialists (pain management or supportive care). * ECOG performance status of 0-3. * Life expectancy is greater than 4 weeks and less than 1 year in the treating physician's judgment.	* Participants with prior cranial or head/neck radiation where cumulative organ-at-risk dose constraints cannot be achieved (see section 4.2). * Inability to have an MRI of the brain for reasons such as a non-compatible bioimplant that could be displaced during MRI, shrapnel embedded (such as from war wounds), metal workers, and machinists (potential for metallic fragments in or near the eyes). * Expressions of pain due to depression, delirium or addictive behavior * Participants who are pregnant. * Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study in the judgment of the Investigators.

Inclusion Criteria

Exclusion Criteria

* Age ≥ 18 years old on the day of signing informed consent and willing and able to sign a written informed consent.
* English fluency in order to complete PROs and neurocognitive assessment
* Pathologic or cytologic confirmation of malignancy.
* Poorly controlled intractable nociceptive or mixed pain limiting function or quality of life. Participants must have exhausted or not a candidate for standard of care pain control measures such as opioids, injections/ablations, conventional radiation therapy, or surgical intervention with a curative intent and pain limiting function that affects the participants quality of life in the judgment of the treating physician. Refractory status will require at least consultation and two follow-up visits with pain specialists (pain management or supportive care).
* ECOG performance status of 0-3.
* Life expectancy is greater than 4 weeks and less than 1 year in the treating physician's judgment.

* Participants with prior cranial or head/neck radiation where cumulative organ-at-risk dose constraints cannot be achieved (see section 4.2).
* Inability to have an MRI of the brain for reasons such as a non-compatible bioimplant that could be displaced during MRI, shrapnel embedded (such as from war wounds), metal workers, and machinists (potential for metallic fragments in or near the eyes).
* Expressions of pain due to depression, delirium or addictive behavior
* Participants who are pregnant.
* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study in the judgment of the Investigators.

Contacts and Locations

Study Contact

Chenyang Wang, MD

CONTACT

(832) 710-1570

cwang23@mdanderson.org

Principal Investigator

Chenyang Wang, MD

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

MD Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Chenyang Wang, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-06

Study Completion Date2027-07-01

Study Record Updates

Study Start Date2025-01-06

Study Completion Date2027-07-01

Terms related to this study

Additional Relevant MeSH Terms

Hypophysectomy